Hepion Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, NJ 08837
| November 22, 2021 |
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
| Re: | Hepion Pharmaceuticals, Inc. |
| Amendment No. 1 to Form S-3 Registration Statement | |
| Filed November 19, 2021 | |
| File No. 333-254996 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Wednesday, November 24, 2021, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
| HEPION PHARMACEUTICALS, INC. | ||
| By: | /s/ Robert Foster | |
| Name: | Robert Foster | |
| Title: | Chief Executive Officer | |
-1-
